Indication
Primary Immunodeficiency
8 clinical trials
10 products
1 drug
Clinical trial
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary ImmunodeficiencyStatus: Completed, Estimated PCD: 2022-07-18
Product
IGSCClinical trial
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral ImmunodeficiencyStatus: Completed, Estimated PCD: 2022-03-28
Product
Gamunex-CProduct
IVIG-PEGClinical trial
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological DisordersStatus: Terminated, Estimated PCD: 2020-06-01
Product
BPX-501Product
RimiducidProduct
rivogenlecleucelClinical trial
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological DisordersStatus: Terminated, Estimated PCD: 2020-06-30
Clinical trial
Safety and Efficacy of Cyclophosphamide and Ruxolitinib for Graft-versus-host-disease Prophylaxis After Hematopoietic Stem Cell Transplantation With Thymoglobulin Serotherapy in Conditioning Regimen in Patients With Inborn Errors of ImmunityStatus: Recruiting, Estimated PCD: 2026-11-21
Drug
cyclophosphamideProduct
RuxolitinibClinical trial
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA Matched Cadaveric Donors (RTB-003)Status: Completed, Estimated PCD: 2024-03-01
Product
CD3/CD19 neg allogeneic BMTClinical trial
Facilitated Immunoglobulin Administration Registry and Outcomes StudyStatus: Completed, Estimated PCD: 2021-11-30
Product
HyQvia